Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Sarepta Therapeutics (SRPT) shares rose 5.56% after the FDA issued a new Boxed Warning and restricted the use of its Duchenne muscular dystrophy gene therapy, Elevidys. Prompted by reports of fatal liver injury in non-ambulatory pediatric patients, the updated label now limits Elevidys to ambulatory patients aged four or older, a clarification that appears to have assuaged investor concerns despite narrowing the therapy's eligible patient population.

Analysis

The U.S. Food and Drug Administration (FDA) issued a new Boxed Warning for Sarepta Therapeutics' (SRPT) Duchenne muscular dystrophy (DMD) gene therapy, Elevidys, citing reports of fatal liver injury in non-ambulatory pediatric patients. Despite this highest-level safety warning and use restriction, SRPT stock reacted positively, closing up 5.56% at $18.81 on Friday, partially recovering from a nearly 50% decline over the past six months.

The updated label now limits Elevidys to ambulatory patients aged four or older with a confirmed DMD gene mutation, a direct response to severe liver enzyme increases and acute liver failure observed in non-ambulatory patients. Sarepta had already voluntarily paused use for non-ambulatory patients, indicating a proactive stance on safety concerns.

The moderately positive market sentiment (0.45) suggests investors perceive the FDA's definitive guidance as a reduction in regulatory overhang, providing clarity for Elevidys' commercial path. While the eligible patient pool is narrowed, the formal restriction allows for continued, albeit more targeted, market access within a safer patient demographic.

Key Decisions for Investors

• Monitor Elevidys' commercial uptake and sales trajectory within the newly defined ambulatory patient population to gauge revenue impact.
• Closely track any further safety data or post-marketing surveillance for Elevidys, especially regarding liver function, as this remains a critical risk factor.
• Evaluate Sarepta's broader pipeline and diversification efforts to mitigate concentration risk associated with a single, label-restricted product.